Table 1 Clinical finding among different eGFR levels at biopsy time.

From: Tubular atrophy/interstitial fibrosis scores of Oxford classification combinded with proteinuria level at biopsy provides earlier risk prediction in lgA nephropathy

 

All (n = 742)

eGFR ≥ 60 (n = 632)

eGFR < 60 (n = 110)

Age(year)

32.7 ± 0.5

31.3 ± 0.4

41.6 ± 1.3*

U-Pro(g/day)

1.5 ± 0.1

1.3 ± 0.1

2.8 ± 0.3*

MAP(mmHg)

95.0 ± 0.5

93.8 ± 0.5

101.6 ± 1.3*

s-Cr(umol/l)

84.9 ± 1.3

74.8 ± 0.9

145.2 ± 4.1*

BUN(mmol/l)

8.6 ± 1.2

8.5 ± 1.4

9.0 ± 0.4

UA(umol/l)

340.5 ± 4.0

327.5 ± 4.0

419.4 ± 12.1

s-Alb(g/dl)

36.1 ± 0.3

36.8 ± 0.3

31.9 ± 1.0*

Hb(g/dl)

127.6 ± 2.1

134.7 ± 3.6

122.2 ± 2.4*

CHOL(mmol/l)

5.5 ± 0.1

5.4 ± 0.1

6.1 ± 0.2*

TG(mmol/l)

1.9 ± 0.1

1.8 ± 0.1

2.1 ± 0.1

IgG(g/l)

10.2 ± 0.2

10.4 ± 0.2

9.5 ± 0.5

IgA(g/l)

2.6 ± 0.0

2.5 ± 0.0

2.8 ± 0.1*

IgA/C3

2.6 ± 0.1

2.6 ± 0.1

2.8 ± 0.1

IgM(g/l)

1.9 ± 0.5

2.0 ± 0.6

1.4 ± 0.1

C3(g/l)

1.0 ± 0.0

1.0 ± 0.0

1.0 ± 0.0

IgA/IgG

0.3 ± 0.0

0.3 ± 0.0

0.5 ± 0.1*

C4(g/l)

0.2 ± 0.0

0.2 ± 0.0

0.3 ± 0.0*

Treatment

301(40.6%)

247(39.1%)

54(49.1%)*

  1. U-Pro, urinary protein excretion; MAP, mean artery pressure; s-Cr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; s-Alb, serum albumin; Hb, hemoglobine; CHOL, cholesterol; TG, triglyceride; Treatment: Use of ARSB or any immonosuppression; *p < 0.05 compared to eGFR ≥ 60 group.
Back to article page